Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Datavault AI Inc. (“Datavault” or the “Company”) (NASDAQ: DVLT). Such investors are...
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuit, Inc. - INTU
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Intuit, Inc. (“Intuit” or the “Company”) (NASDAQ: INTU). Such investors are advised to...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BP p.l.c. (“BP” or the “Company”) (NYSE: BP). Such investors are advised to contact...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aether Holdings, Inc. (“Aether” or the “Company”) (NASDAQ: ATHR). Such investors are...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS). Such investors are advised to...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI). Such investors...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UP Fintech Holding Limited (“UP Fintech” or the “Company”) (NASDAQ: TIGR). Such investors...
-
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to...